National Storage Mechanism | Additional information
RNS Number : 4093T
S-Ventures PLC
25 March 2021
 

25 March 2021

 

S-VENTURES PLC

("S-Ventures" or the "Company")

 

OTCQB APPLICATION

 

S-Ventures (Aquis Exchange: SVEN), is pleased to announce that it has filed an application with OTC Markets Group for the Company's shares to be cross-traded publicly on the OTCQB Venture Market which would make S-Ventures shares more widely available to North American investors.

 

Trading on the US OTCQB market would have no impact on existing S-Venture's ordinary shares trading on the AQSE Growth Market and no new ordinary shares will be issued as part of the cross-trade. SVEN will continue to rely on the announcements and disclosures it makes to the Aquis Exchange and will have no Sarbanes-Oxley or SEC reporting requirements.

 

Should the application be successful, the cross-trading facility will be provided through OTC Markets

Group Inc., located in New York, USA. OTC Markets operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-traded companies.

 

Scott Livingston, Chief Executive of S-Ventures PLC, said: "We would like to make S-Ventures PLC available to US markets in order to gain access to a broader investor base and enhance our visibility in

North America, where many of our potential customers are based. Cross trading on the OTC markets

represents an important development for the company." 

 

The directors of the issuer accept responsibility for the contents of this announcement.

 

For further information, please contact:

The Company

Robert Hewitt                                                                          +44 (0) 1932 400 224


[email protected]


AQSE Corporate Adviser:

Peterhouse Capital Limited


Guy Miller/Allie Feuerlein                                                    +44 (0) 20 7469 0936


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXDKQBQFBKDFNB